PYPD — PolyPid Ltd.

Summary of PolyPid's Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Financials:

  • Research and Development (R&D) expenses: $6.2 million (down from $7 million in Q4 2024).
  • General and Administrative (G&A) expenses: $1.8 million (up from $1 million in Q4 2024).
  • Marketing and Business Development expenses: $0.6 million (up from $0.2 million in Q4 2024).
  • Net loss: $8.5 million or $0.41 per share (compared to a net loss of $8.5 million or $1.13 per share in Q4 2024).

• Full Year 2025 Financials:

  • R&D expenses: $23.8 million (up from $22.8 million in 2024).
  • G&A expenses: $7.2 million (up from $4.3 million in 2024).
  • Marketing and Business Development expenses: $2 million (up from $0.9 million in 2024).
  • Net loss: $34.2 million or $2.09 per share (compared to a net loss of $29 million or $4.91 per share in 2024).
  • Cash position as of December 31, 2025: $12.9 million, with an additional $3.7 million raised from warrant exercises post-quarter.

2. Strategic Updates and Business Highlights

• Successfully completed the SHIELD II Phase III trial for D-PLEX100, achieving primary and key secondary endpoints, demonstrating a significant reduction in surgical site infections.
• Received positive FDA feedback supporting a rolling NDA submission for D-PLEX100, expected to begin by the end of Q1 2026.
• Advanced discussions with potential U.S. commercial partners, indicating strong interest in D-PLEX100's clinical profile.
• Introduced Kynatrix, a new technology platform expanding beyond localized delivery of small molecules to address systemic therapeutic needs, including a long-acting GLP-1 Receptor Agonist program.
• Appointed Brooke Story as Chairman of the Board, enhancing leadership for commercialization efforts.

3. Forward Guidance and Outlook

• 2026 is anticipated to be transformative for PolyPid, with the rolling NDA submission and ongoing partnership discussions.
• Existing cash resources are expected to fund operations into the second half of 2026, supporting significant upcoming milestones.

4. Bad News, Challenges, or Points of Concern

• The net loss increased year-over-year, indicating ongoing financial challenges as the company transitions from R&D to commercialization.
• The need for successful partnership agreements and market access strategies remains critical, with potential delays in uptake post-approval.
• The competitive landscape for surgical infection prevention and metabolic disease treatments may pose risks to market entry and share.

5. Notable Q&A Insights

• Management confirmed the initial label for D-PLEX100 will focus on preventing surgical site infections in abdominal colorectal surgery, with potential for future label expansion.
• Discussions with the FDA indicated a favorable view of the SHIELD II trial data, which is crucial for NDA submission.
• The company is focused on building awareness and preparing for market access, including health economics research and KOL engagement.
• The Kynatrix platform is an evolution of existing technology, with ongoing R&D efforts leveraging past work to expedite future product development.

Overall, PolyPid is positioned for significant developments in 2026, with a clear focus on regulatory progress and commercialization, despite ongoing financial losses and the challenges inherent in transitioning to a commercial entity.